Johnson & Johnson (HAM:JNJ)
€ 232.4 +0.30 (+0.13%) Market Cap: 551.30 Bil Enterprise Value: 575.65 Bil PE Ratio: 30.77 PB Ratio: 7.53 GF Score: 83/100

Johnson & Johnson at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2026 / 03:30PM GMT
Terence Flynn
Morgan Stanley - Analyst

Great. Thanks so much, everybody. Good afternoon. I'm Terence Flynn, Morgan Stanley's US biopharma analyst.

For important disclosures, please see Morgan Stanley's research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

So I'm very pleased to be hosting Johnson & Johnson this afternoon. Joining us from the company, we have Joaquin Duato, the company's CEO and Chairman; and John Reed, Executive Vice President, Innovative Medicine, R&D. But thank you both so much for taking time out of your busy schedules to join us, really appreciate it.

Questions & Answers

Terence Flynn
Morgan Stanley - Analyst

Maybe we'd start, I thought high level, Joaquin. The company laid out some long-term growth targets at the December 2023 Enterprise Business Review Meeting. And so maybe you could just level set us in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot